4503 Astellas Pharma
- 1733.0
- +22.0+1.29%
Astellas Pharma News
Astellas Pharma: Japan’s Ministry of Health, Labour and Welfare Approves PADCEV with KEYTRUDA for First-Line Treatment of Radically Unresectable Urothelial Carcinoma
Astellas Pharma: Antibody-drug complex Padceb obtains approval for additional indications in Japan for combination therapy with pembrolizumab as primary treatment for unresectable urothelial cancer
Astellas Pharma: Astellas Receives Approval from the EC for VYLOY in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer
Astellas Pharma: VYLOY (zolbetuximab) approved in Europe for use in combination with chemotherapy for locally advanced or metastatic gastric adenocarcinoma and esophagogastric junction adenocarcinoma
Astellas Pharma: Notice Regarding Issuance of Unsecured Bonds
Astellas Pharma: Notice Concerning Issuance of Unsecured Ordinary Corporate Bonds
Astellas Pharma: Supplementary Issuance Registration Documents (Stock Certificates, Corporate Bonds, etc.)
Astellas Pharma: European Commission Approves Astellas’ PADCEV in Combination with KEYTRUDA for First-Line Treatment of Advanced Urothelial Cancer
Astellas Pharma: Antibody-drug complex PADCEV (enforzumab vedotin) obtained approval in Europe for combination therapy with pembrolizumab for primary treatment of patients with advanced urothelial cancer
Astellas Pharma: China's National Medical Products Administration has approved PADCEV as a treatment for locally advanced or metastatic urothelial carcinoma.
Astellas Pharma: PADCEV (Enfortumab vedotin), an Antibody-Drug Conjugate, has obtained approval in China.
Astellas Pharma: Presentation materials for the briefing session (1st quarter of fiscal year 2024).
Astellas Pharma: Financial results (Q1/Fiscal Year 2024).
Astellas Pharma: Announcements of individual stock volatility in fair value of contingent consideration.
Astellas Pharma: About recording the fair value change of consideration related to conditions.
Astellas Pharma: Earnings conference materials for Q1 of the fiscal year ending March 2025.
Astellas Pharma: Supplemental materials for the first quarter financial statements of March 2025.
Astellas Pharma: Supplementary Documents (Q1 FY2024)
Astellas Pharma: March 2025 first quarter financial results announcement [IFRS] (consolidated)
Astellas Pharma: Astellas Pharma has received a positive opinion from the CHMP regarding the combination of zolbetuximab and chemotherapy in the treatment of advanced gastric and gastrointestinal cancers.
Analysis
Price Target
No Data
No Data